T1	p 177 190	breast cancer
T2	p 326 341	breast cancer .
T3	p 480 513	receiving chemotherapy for breast
T4	p 827 875	chemotherapy-na?ve patients with breast cancer .
T5	p 1108 1157	. Median age of the 94 women was 51 years ( range
T6	p 1237 1297	doxorubicin/cyclophosphamide . Thirteen withdrew pre-cycle 2
T7	i 32 50	placebo-controlled
T8	i 115 128	dexamethasone
T9	i 151 172	adjuvant chemotherapy
T10	i 309 321	chemotherapy
T11	i 364 377	dexamethasone
T12	i 490 502	chemotherapy
T13	i 528 567	treatment with dexamethasone or placebo
T14	i 762 779	dexamethasone ( 4
T15	i 808 822	versus placebo
T16	i 827 845	chemotherapy-na?ve
T17	i 898 977	intravenous granisetron and dexamethasone pre-chemotherapy and oral granisetron
T18	i 1168 1170	79
T19	i 1180 1227	fluorouracil/epirubicin/cyclophosphamide and 15
T20	i 1237 1267	doxorubicin/cyclophosphamide .
T21	i 1384 1391	placebo
T22	i 1467 1482	dexamethasone ;
T23	i 1676 1694	dexamethasone . No
T24	i 1862 1886	dexamethasone or placebo
T25	i 1902 1925	adjuvant chemotherapy .
T26	o 85 100	quality of life
T27	o 266 293	delayed nausea and vomiting
T28	o 403 424	, anxiety/agitation ,
T29	o 592 621	delayed nausea and vomiting ,
T30	o 637 660	quality of life ( QOL )
T31	o 1028 1038	preference
T32	o 1084 1090	of QOL
T33	o 1348 1368	stating a preference
T34	o 1371 1373	31
T35	o 1535 1598	intensity of vomiting , nausea , or time to onset of vomiting .
T36	o 1617 1641	decrease in global QOL (
T37	o 1701 1720	symptom/QOL domains
T38	o 1809 1839	preference , QOL , or symptoms